In contrast, the administration of brusatol, an Nrf2 inhibitor, significantly reverses the positive regulatory effects of metformin on the Nrf2/GPX4 signaling pathway and reduces its hepatoprotective effects in NAFLD models. The gene discussed is GPX4; the disease is metabolic dysfunction-associated steatotic liver disease.